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| INTRODUC TI ON
Dendritic cells are the most potent and specialized antigen-presenting cells that play a central role in host-antitumor immunity. The imDCs are present in non-lymphoid tissues. Following the capture of antigens, they travel through blood or lymph to secondary lymphoid organs, and gradually differentiate into mDCs that upregulate the expressions of peptide-MHC complexes and accessory molecules (eg, CD11c, CD80, CD83, CD86, and CCR7 et al) on their surfaces, which are necessary for naive T-cell activation, leading to immune response or tolerance. 2, 3 The motility of DCs is important for migration of imDCs in peripheral tissues and physical interaction between mDCs and naïve T cells in secondary lymph nodes. 4 Dendritic cells can conduct all the elements of the immune orchestra. Information on the interaction between mDCs and naïve T cells can be developed for novel clinical therapy against immune-related diseases. 5 Dendritic cell-based immunotherapies against cancers have achieved some promising successes, but there are still many challenges, 1, 6 in which the impaired motility and immune function of mDCs by tumor microenvironment-derived suppressive cytokines, including VEGF, transformed growth factor-β 1 , and interleukin-10, are not well characterized. 5, 7 Villablanca et al 8 found that the tumor-derived factors can inhibit the immune function of mDCs through CCR7.
Herber et al 9 reported that DCs in the tumor-bearing host upregulate the capability of triglyceride uptake through scavenger receptor A, leading to lipid accumulation in cells and impaired motility and immune function. Although our previous studies showed that the biophysical properties and motility of human mDCs deteriorated by VEGF through cytoskeleton remodelling, 10 its action target is still elusive.
Vascular endothelial growth factor is excreted by most cancer cells to stimulate the proliferation of endothelial cells and function as an angiogenic factor in vivo. 11 The infiltration and density of DCs are directly correlated with positive prognosis. Moreover, DC density is negatively associated with VEGF level in vivo. 12 Vascular endothelial growth factor can inhibit the functional maturation of imDCs 13, 14 and impair the differentiation of DCs. 13, 15 As a mAb of VEGF, bevacizumab has achieved great successes in the clinical field of tumors, but many problems still need to be solved, such as toxic side-effects, inaccurate curative effect, and inaccurate targeting. 16, 17 Several groups have established that the blockade of the VEGF signaling pathway by various strategies can partially recover the function of DCs in vivo and in vitro. 18 The VEGF receptor-1 and VEGFR2 play different roles in DC differentiation. 
| MATERIAL S AND ME THODS

| Isolation of monocytes and generation of DCs
Dendritic cells were generated from fresh PBMCs of healthy human subjects as described by Steinman 21 with minor modifications according to our previous protocol. 10 All donors gave informed consent and the study protocol was approved by the ethics committee of Guizhou Medical University (Guiyang, China). FicollPaque gradient centrifugation was deployed to enrich CD14 + monocytes and cocktail immunomagnetic beads (Dynal, ThermoFisher Scientific) was used for further purification. The PBMCs were cultured in RPMI-1640 medium supplemented with 15% FBS (Gibco), 1% penicillin/streptomycin, 150 ng/mL recombinant human granulocyte-macrophage colony stimulating factor, and 100 ng/mL recombinant human interleukin-4 (Peprotech).
On the seventh day, recombinant human tumor necrosis factor-α (Peprotech) was added to the final concentration of 10 ng/mL.
After 72 h culture, the phenotypes of DCs were analyzed using flow cytometer (BD FACScan) by staining the cell surface markers of CD11c, CD40, CD80, CD83, CD86, CCR7, and HLA-DR. Trypan blue dye was used to measure cell viability.
| Culture of HUVECs and T cells
Human umbilical vein endothelial cells were cultured in terms of our previous protocol. [22] [23] [24] [25] T cells were separated from the PBMCs by RosetteSep human T cell enrichment cocktail (StemCell) in accordance with the manufacturer's recommendations.
| Treatments of mDCs
Mature DCs were harvested and treated with or without 50 ng/ mL recombinant human VEGF-165 (rhVEGF-165; R&D Systems) for 24 hours at 37°C according to the procedures described by Mimura et al. 20 The working concentrations were determined based on previous reports 9,10,15,22 and our preliminary experiments. As an inhibitor for RhoA signaling and BP for P-COF1, 10 μmol/L Y27632 (Sigma) and 1 μg/mL Ser3-P-COF1 BP (ECM Biosciences), as well as the BAs of goat anti-human VEGFR1 mAb (10 μg/mL) and mouse anti-human VEGFR2 mAb (50 ng/ mL), 20 were respectively applied to treat mDCs for 30 minutes before administration of rhVEGF-165. Untreated mDCs and mDCs treated with 50 ng/mL mouse anti-human IgG (Sigma) served as blank and negative controls, respectively.
| Analyses of 2-D gel-based proteomics
To minimize individual differences and obtain sufficient quantity of proteins for 2-D gel, the protein extracts of 7 preparations of mDCs from seven healthy individuals were combined after cell characterization to form a pool of protein extracts. The 2-D gels were obtained according to our previous protocol. 25 The resulting peptides from 2-D gel were extracted with TFA/acetonitrile/water, and the peptide mixtures were analyzed by MALDI TOF (Shimadzu) using α-cyano-4-hydroxy-cinnamic acid as a matrix on a plate with delayed extraction or Q-TOF Ultima Global (Waters). Identification of the proteins using these mass fingerprinting data was undertaken using the Mascot software (Matrix Science). 
| Measurements of mRNA levels by qRT-PCR
| Measurements of Rho GTPase activity by pulldown assay
Affinity purification assays of CDC42, RhoA, and Rac activation are based on the fact that these proteins act as molecular switches, cycling between inactive GDP-bound and active GTP-bound states.
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The expression levels of CDC42, RhoA, and Rac were measured by the CDC42/RhoA/Rac activation assay kits (Upstate Biotechnology)
according to the manufacturer's protocols. The secondary Abs were HRP-conjugated IgG Ab. The immunoblot was processed and treated with chemiluminescent reagents (Pierce), and the bands were visualized in the ECL system.
| Measurement of TMCs in Transwell chambers
Human umbilical vein endothelial cell monolayers were seeded onto the upper compartment surface of the microporous membrane of a Transwell chamber (5 μm pores; Corning). Cells ( 10 6 ) were added onto the HUVEC monolayers and incubated at 37°C for 12 hours.
As the chemokine for mDCs, 0.6 μg/mL CCL21 (R&D Systems) was added to the lower compartment. Cells collected from the lower compartment were counted with FACScan. The ratio of the cell counts in the lower compartment to that added to the upper compartment was calculated to represent the cell TMCs.
| Mixed leukocyte reaction assay
The immune stimulatory capabilities of mDCs were determined by the primary allogeneic MLR assay as described in our previous protocol, 22-25 using human T lymphocytes as responder cells.
| Localizations of P-COF1 and COF1 by immunofluorescence
Cells were collected and fixed as described. 
| RE SULTS
| Analyses of proteomics and RT-PCR validation
The effects of VEGF on mDCs were investigated by 2-D-based proteomics, with mDCs + IgG as control ( Figure 1A -C). Numerous changes in the relative abundance of a particular protein were reproducibly detected. From the spots differentially expressed between control mDCs and VEGF-treated mDCs, 33 protein spots were successfully identified (Table 2) , in which No. 24 protein was confirmed as COF1 by Q-TOF Ultima Global ( Figure 1E ), a cytoskeleton-binding protein that showed interesting expression changes. As shown in Figure 1D , the "lost" tail appeared in the No.
24 protein spot of mDCs after treatment with VEGF. The spots of the same protein with different pI could be related to phosphorylation or acetylation, and were visualized in 2-D as a "train of spots". 27 Therefore, it could be inferred that the COF1 in mDCs treated with VEGF has an abnormal phosphorylation modification.
As shown in Figure 2B , the ratios of P-COF1 to total COF1 were increased (P < .01), suggesting that the P-COF1 levels in mDCs were upregulated by VEGF.
| Expression levels of Rho GTPase
The upstream signaling of COF1 is associated with members of the Rho GTPase family, including Rac, CDC42, and RhoA. 28 The mDCs under different conditioned media expressed VEGFR1 and VEGFR2
(data not shown). The expression levels of Rac, CDC42, and RhoA were analyzed by pull-down assay and western blotting. The results showed that VEGF caused an increase in RhoA, but no changes in Rac or CDC42 (data not shown). To investigate the role of RhoA in VEGF signaling, mDCs were treated with Y27632, an inhibitor of Rho-associated coiled-coil containing protein kinase. As shown in Figure 2A , the expressions of RhoA-GTPase in mDCs treated with VEGF were upregulated (P < .01), and this effect disappeared after treatment with Y27632 plus VEGF, suggesting that RhoA is downstream of VEGF.
| Expression levels of P-COF1 and total COF1
Cofilin1 is an essential protein responsible for high turnover rates of actin filaments in vivo, which can induce a twist in the filament, 
F I G U R E 2
The RhoA-COF1 pathway is a downstream signal of vascular endothelial growth factor (VEGF) in mature dendritic cells (mDCs). mDCs were harvested and treated with 50 ng/mL rhVEGF-165 for 24 h. RhoA specific inhibitor Y27632 was applied to mDCs for 30 min before treatment with VEGF-165. A, RhoA is a downstream signal of VEGF in mDCs. Representative western blotting image (mean ± SD, n = 4), **P < .01. B, Expression levels of phosphorylated (P-)COF1 in mDCs are enhanced by VEGF through RhoA signaling. Representative western blotting images (mean ± SD, n = 5), **P < .01
F I G U R E 3 Motility and immune regulation function of mature dendritic cells (mDCs) impaired by vascular endothelial growth factor (VEGF) through
RhoA-COF1 signaling. A, Transmigration capabilities of mDCs are impaired by VEGF through Rho-COF1 signaling. mDCs were treated with 50 ng/mL rhVEGF-165 for 24 h. RhoA specific inhibitor Y27632 was applied to mDCs for 30 min before treatment with VEGF-165. mDCs were treated with phosphorylated (P-)COF1 blocking peptide (BP) to assess the role of phosphorylation levels of COF1 in mDC migration. In Transwell assay, the ratio of the cell counts in the lower compartment to that added to the upper compartment represents the transendothelial migration percentage of cells, which reflects cell transmigration capabilities (TMCs) (mean ± SD, n = 4). Compared with control, **P < .01. B, Immune stimulatory capabilities of mDCs were inhibited by VEGF through RhoA-COF1 signaling. mDCs were added in graded doses ( accelerate the release of Pi from ADP-Pi subunits, and sever F-actin into G-actin; moreover, the severing activity is greatly reduced by phosphorylation. 29 As shown in Figure 1F , the mRNA expression level of total COF1 was upregulated by VEGF. Measurement of the phosphorylation levels of COF1 in mDCs by western blotting ( Figure 2B ) showed that the expression levels of P-COF1 were upregulated by VEGF (P < .01), and that the level recovered to normal when pretreated with Y27632, indicating that the expression levels of P-COF1 were enhanced by VEGF through RhoA signaling.
| Transendothelial migration capabilities
The TMCs of mDCs, which are very important for their antigen presentation, primarily depend on the reorganization of F-actin cytoskeleton. [22] [23] [24] [25] It was hypothesized that the upregulation of P-COF1 caused by VEGF could reorganize cytoskeletal structure and impair the motility of mDCs. Therefore, the cell TMCs were investigated by using the Transwell chamber. As shown in Figure 3A , the TMCs of mDCs were markedly impaired by VEGF (P < .01). To further investigate the role of RhoA and P-COF1 in transmigration, mDCs
were treated with Y27632 and P-COF1 BP, respectively, and their
TMCs were also decreased. These results support the notion that the TMCs of mDCs are impaired by VEGF and RhoA-COF1 signaling is involved in regulating the migration of mDCs.
| Immune stimulatory capabilities
The motilities of mDCs are closely related to their ISCs. [2] [3] [4] The results of MLR ( Figure 3B ) showed that the stimulatory capabilities of mDCs were reduced by VEGF at all ratios of mDCs to T cells from 1:1 to 1:100. Simultaneously, Y27632 or P-COF1 BP could also decrease the ISCs of mDCs, which might due to the disruption of their proper immune function. These results indicated that RhoA-COF1 signaling is an important pathway in exerting normal immune functions and could be involved in the inhibition effects of VEGF.
| Involvement of VEGF receptor in RhoA-
COF1 signaling
Dendritic cells at different differentiation stages can express VEGFR1 and VEGFR2 at various levels. 19, 20 To identify which VEGFR is involved in RhoA-COF1 signaling, the blocking Abs of VEGFR1
and VEGFR2 were applied to treat mDCs. The results showed that VEGFR2 blocking Ab plus VEGF, in comparison with VEGF alone, decreased the expressions of RhoA-GTPase ( Figure 4A ) and P-COF1
( Figure 4B ) in mDCs (P < .01) and improved the cell TMCs ( Figure 5) (P < .01), suggesting that the motilities of mDCs were impaired by VEGF through VEGFR2.
F I G U R E 4
The RhoA-COF1 signaling pathway afftected by vascular endothelial growth factor (VEGF) through VEGF receptor 2 (VEGFR2). Mature dendritic cells (mDCs) were treated with 50 ng/mL rhVEGF-165 for 24 h. Blocking Abs (BAs) of VEGFR1 and VEGFR2 were applied to mDCs for 30 min before treatment with rhVEGF-165. A, VEGF affected the expression of RhoA-GTPase in mDCs through VEGFR2. Representative western blotting images (mean ± SD, n = 4), **P < .01. B, VEGF increased the expression of phosphorylated (P-)COF1 in mDCs through VEGFR2. Representative western blotting images (mean ± SD, n = 5), **P < .01
The transmigration capabilities (TMCs) of mature dendritic cells (mDCs) decreased by vascular endothelial growth factor (VEGF) through VEGF receptor 2 (VEGFR2). mDCs were treated with 50 ng/mL rhVEGF-165 for 24 h. The blocking Abs (BAs) of VEGFR1 and VEGFR2 were applied to mDCs for 30 min before treatment with VEGF-165. In Transwell assay, the ratio of the cell counts in the lower compartment to that added to the upper compartment represents the cell TMCs. Summation of results on TMCs of mDCs (mean ± SD, n = 4), **P < .01
| Localization of P-COF1 and COF1 in mDCs
The regulatory functions of COF1 are related to their spatial distribution in the cytoplasm. 30 The localization of COF1 (green), P-COF1
(magenta), and F-actin (red) in mDCs treated with or without VEGF were identified by immunofluorescence staining and confocal laser scanning microscopy. As shown in Figure 6 , COF1 and P-COF1 colocalized throughout the cytoplasm of mDCs (about 85%). Following treatment with VEGF, they translocated toward to the plasma membrane of mDCs (about 70%), indicating that the localizations of COF1
and P-COF1 in mDCs were altered by VEGF.
| D ISCUSS I ON
The impairments of DCs by tumor-derived suppressive cytokines are key challenges for DC-based immunotherapies against cancers.
1-3
The defective function of DCs in tumor-bearing hosts has been confirmed by many groups. 1, [5] [6] [7] Moreover, it has been established that the functional maturation and differentiation of imDCs are inhibited and vitiated by VEGF. 31 The present study focuses on the effects of VEGF on the motility and immune stimulatory capability of mDCs, as well as the potential molecular mechanism.
In order to explore the mechanism of VEGF-induced impairment of mDC function at the protein level, the protein expression profiles were investigated by mass spectrography-based proteomics technology. A total of 33 proteins with differential expression were successfully identified (Table 2) , which were associated with the cytoskeleton, migration, antigen presentation, and metabo- Cofilin1, a family of related proteins with similar biochemical activities called the actin depolymerizing factor/COF family, 29, 30 are ubiquitous among eukaryotes and essential proteins responsible for high turnover rates of actin filaments in vivo, which can increase both the number of free barbed ends for polymerization and the rate of actin depolymerization (hence replenishing Gactin in the cell). 32 Cofilin can induce a twist in the filament, accelerate the release of Pi from ADP-Pi subunits, and sever actin filaments into G-actin. Their severing activity is greatly reduced by phosphorylation of upstream signaling molecules, including Rho GTPase. 29, 33 Therefore, we investigated the expression changes of Rho GTPase, including RhoA, Rac, and CDC42, by pull-down assay and western blotting. As shown in Figure 2A , the levels of RhoA-GTPase were upregulated by VEGF, and this change was abrogated by pretreatment with Y27632. These results indicated that the levels of RhoA GTPase in mDCs were regulated by VEGF. Vascular endothelial growth factor did not cause any change in Rac and CDC42 (data not shown). To explore whether the phosphorylation levels of COF1 were regulated by VEGF through RhoA signaling, the expression levels of P-COF1
and total COF1 were measured. The results ( Figure 2B ) showed that the phosphorylation levels of COF1 in mDCs were upregulated by VEGF, confirming the existence of the VEGF-RhoA-COF1 signaling pathway in mDCs. Verdijk et al 34 found that cofilin is dephosphorylated during DC maturation. Therefore, the elevated phosphorylation levels of COF1 in DCs induced by F I G U R E 6 Localization of cofilin1 (COF1) and phosphorylated (P-)COF1 in mature dendritic cells (mDCs) changed by vascular endothelial growth factor (VEGF). mDCs were fixed with 4% paraformaldehyde and permeabilized with 0.3% Triton X-100 in PBS. Cells were blocked in 5% BSA/PBS and incubated with goat anti-human COF1 Ab labelled by Alexa Fluor-488 and rabbit anti-human P-COF1 (Ser3) Ab labelled by Alexa Fluor-350. Cells were stained for F-actin using Alexa Fluor-594 phalloidin. COF1 and P-COF1 were colocalized throughout the cytoplasm of mDCs and translocated to the plasma membrane of mDCs after treatment with VEGF VEGF could lead to the impaired motility and immune function of mDCs. To assess this possibility, transendothelial migration and MLR experiments were carried out, as shown in Figure 3 . The migration and ISCs of mDCs were regulated by VEGF and the RhoA-COF1 pathway might be involved in the functional impairment of mDCs. In addition, the migration and immune function of mDCs were inhibited by Y27632 and P-COF1 BP, which could be due to the reduced actin polymerization and disappearance of dendrites. 26 Vascular endothelial growth factor signaling is also transduced by way of several other intracellular signaling pathways, including Erk, p38MAPK, or the serine/threonine protein kinase Akt, leading to increased cell proliferation, survival, permeability, and migration of endothelial cells. 35 It was reported that VEGF can enhance the phosphorylation of Erk1/2, but not those of p38MAPK or Akt in mDCs. 36 Moreover, our results and those from other groups showed that VEGF can impair the immune function through the NF-κB pathway. 13, 37 From these results, it could be inferred that the molecular targets of VEGF to mDCs were COF1, Erk1 and 2, and NF-κB, all of which are related to the cytoskeleton, motility, and gene transcription.
Vascular endothelial growth factor acts through a series of tyrosine kinase receptors, including VEGFR1, 2, and 3 and neuropilin 1 and 2 and its binding sites have been identified on vascular endothelial cells, monocytes, mDCs, and other cell types. 38 Among the VEGFRs, mDCs can express VEGFR1 and VEGFR2. In summary, the present study showed that VEGF can impair the motility and immune function of mDCs through the RhoA-COF1 pathway mediated by VEGFR2. First, as shown in Figure 7 , VEGF binds to VEGFR2 on the mDC membrane, leading to upregulation of RhoA-GTPase. Second, the increased RhoA-GTPase upregulates the expression of P-COF1 to cause dysfunction of de novo F-actin. 
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